5th Gene Therapy for Ophthalmic Disorders Summit

Kongressthemen
Ophthalmic drug developers are unlocking the full potential of gene therapy. Crucial lessons learnt from both clinical successes and failures, coupled with recent improvements in development and delivery, means that the space is poised to capitalize on the significant potential of the eye as a target for genetic medicine approaches.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
URL:
Brochure: https://go.evvnt.com/2478440-2?pid=4832

Speakers: Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Adam Silverman, Vice President - Protein Sciences, Spotlight Therapeutics, and more

https://go.evvnt.com/2478440-3?pid=4832

Frau Mara Mihailovic